Pharmacological Targeting of Constitutively Active Truncated Androgen Receptor by Nigericin and Suppression of Hormone-Refractory Prostate Cancer Cell Growth
Here investigators established a reporter system that monitors androgen receptor-mediated activation of a prostate specific antigen promoter. [Mol Pharmacol]

Inactivation of the WASF3 Gene in Prostate Cancer Cells Leads to Suppression of Tumorigenicity and Metastases
The WASF3 protein is involved in cell movement and invasion, and to investigate its role in prostate cancer progression scientists studied the phenotypic effects of knockdown in primary tumors and cell lines. [Br J Cancer]

Epigenetic Silencing of SOCS3 Identifies a Subset of Prostate Cancer with an Aggressive Behavior
The data suggest that suppressor of cytokine signaling 3 (SOCS3) hypermethylation may be involved in the pathogenesis of prostate cancer and could identify a tumor subset with an aggressive behavior. [Prostate]

Statins Reduce the Androgen Sensitivity and Cell Proliferation by Decreasing the Androgen Receptor Protein in Prostate Cancer Cells
In the present study, scientists determined the molecular mechanisms related to the regulation of prostate-specific antigen, androgen receptor and cell proliferation in prostate cancer cell lines by statins. [Prostate]

Type-1 Polarized Dendritic Cells Loaded with Apoptotic Prostate Cancer Cells are Potent Inducers of CD8+ T Cells Against Prostate Cancer Cells and Defined Prostate Cancer-Specific Epitopes
In order to develop improved vaccines for patients with recurrent prostate cancer (PCa), investigators tested the feasibility of using type-1 polarized dendritic cells to cross-present antigens from allogeneic PCa cells and to induce functional CD8+ T cell responses against PCa cells and against defined MHC class I-restricted PCa-relevant epitopes. [Prostate]

CLINICAL RESEARCH

Effects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates
The aim of this study was to investigate whether increased diagnostic activity is related to the incidence of prostate cancer among brothers of men with prostate cancer. [J Natl Cancer Inst]

Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans
To describe patterns of biochemical recurrence and subsequent mortality, researchers conducted an observational study in a community-based, "high-comorbidity" setting of 623 US veterans diagnosed as having prostate cancer from 1991 to 1995 and receiving radical prostatectomy or radiation therapy. [Arch Intern Med]

Knowledge and Use of Finasteride for the Prevention of Prostate Cancer
Investigators examined the influence of the Prostate Cancer Prevention Trial on finasteride prescribing within the Veterans Health Administration. [Cancer Epidemiol Biomarkers Prev]

Raman Spectral Imaging of Prostate Cancer: Can Raman Molecular Imaging be Used to Augment Standard Histopathology?
The purpose of the study is to evaluate whether Raman molecular imaging (which combines digital imaging and analytical spectroscopy to evaluate the biochemical composition of interrogated material) can be used to identify biochemical differences in patients with Gleason 7 prostate cancer who progress to metastatic disease and die from prostate cancer. [BJU Int]

Metronomic Administration of Zoledronic Acid and Taxotere Combination in Castration Resistant Prostate Cancer Patients. Phase I ZANTE Trial
Twenty-two patients enrolled into the study (median age: 73 years; range: 43-80) received one of three escalated doses of docetaxel (DTX) [30, 40 and 50mg/m(2)] in combination with a fixed dose of zoledronic acid (ZOL) (2mg), both administered every 14 days in two different sequences: DTX at the day 1 followed by ZOL at the day 2 (sequence A) or the reverse (sequence B). Patients were evaluated for adverse events and serum IL-8, MMP-2 and MMP-9 were evaluated prior and after therapy with the two sequences of administration of DTX and ZOL. [Cancer Biol Ther]

Incidence of Insignificant Prostate Cancer Using Free/Total PSA: Results of a Case-Finding Protocol on 14453 Patients
The aim of this study is to evaluate prostate cancer (PCa) detection and incidence of pathologically insignificant PCa (pIPCa) tumour using percent-free PSA (%f-PSA) in patients with total PSA less than or equal to 10 ng/ml. [Prostate Cancer Prostatic Dis]